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I. REVIEW O]~ THE LITERATURE 
1.  Nature and Experimental Variation 
Hildebrandt (1893), Camus and Gley (1897), and Landsteiner (1900)  were the first 
investigators to observe that normal serum markedly inhibits  the action of trypsin 
and of yeast proteases.  Opie (1905)  and Jochmann  (1908)  demonstrated its ability 
to  inhibit  leucoprotease.  Study  of  numerous  species  of  animals  (Launoy,  1919) 
showed antiproteolytic  activity to be a  constant  property of mammalian and  bird 
serum, but innumerable investigations have as yet led to little success in the identifica- 
tion of the substance or substances responsible for this property. 
The earliest, and still prevalent, theory of the origin of serum antiprotease is that 
it is a protective antibody formed by the body against proteolytic ferments emptied 
into the blood stream.  This idea had its inception in the work of Achalme (1901) 
and Meyer (1909), who reported an increase in the antiproteolytiO activity of serum 
in response to intraperitoncal injection of trypsin into guinea pigs.  This finding was 
refuted  by some investigators  (e.g., Bergeil and  Schutze,  1905;  Young,  1918),  but 
confirmed and  extended  by Jochmann  and  Kantorowicz  (1908),  who demonstrated 
a  rise in activity following subcutaneous injection of leucoprotease into rabbits, and 
who concluded from this that leucoprotease serves as the normal antigen in response 
to which antiprotcase is produced. 
Others (e.g., yon Bergmann and Gulecke, 1910) postulated that the pancreas rather 
than the leucocytes supplied the hypothetical protease antigen, and offered evidence 
that the antiproteolytic activity on the serum increases following implantation of the 
pancreas into the peritoneal cavity. 
This  seemed to be supported  by the  work of Cobliner  (1910),  who showed  that 
serum  antiproteolytie  activity  decreases  considerably  following  extirpation  of  the 
pancreas. 
Indirect  evidence  against  the  antibody  theory has  come from Landsteiner's  re- 
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x The term "antiproteolytic"  is here used to represent the ability to inhibit many 
animal and plant proteases which are active at about neutral pH.  Trypsin is  the 
protease used in this, and most other experimental work, but inhibition of  leucopro- 
tease and of other proteolytic enzymes has repeatedly been demonstrated. 
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peatedly confirmed observation  (1900) that antiprotease activity is a property of the 
albumin fraction of serum, whereas antibody activity is a property of the globulin 
fraction.  Furthermore, there is general agreement that increased enzyme-inhibiting 
action of serum, when it occurs, rarely exceeds three or four times the original degree of 
inhibition, in contrast to true antibodies, which increase to the extent of thousands 
of times the original antibody content of the blood in response to injections of antigen. 
Impressed by these considerations, and  by his discovery that charcoal inhibited 
trypsin by adsorbing it, Hedin (1906-07) attempted to prove that serum exerted its 
antiprotease  action  by adsorption  of  the  enzyme,  supposedly  by serum  albumin. 
Many of the more recent workers, notably Banting and Gaims (1930), Fine (1931), and 
Chrometzka ("neurohormonal regulation" theory, 1932) have accepted Hedin's idea, 
largely on theoretical grounds.  But Hanson (1918) was unable to find any variation 
in the concentration of serum protein when the antiproteolytic activity of the serum 
was doubled, or even tripled. 
A third group of workers followed the lead of Schwartz (1909) and Bauer (1910), 
who observed that  after serum antiproteolytic activity had been  "extracted"  with 
ether, it could be restored by the addition of lipoids to the serum.  This group at- 
tempted to prove (Jobling and Petersen,  1914)  that the antiproteolytic activity of 
serum is due  to its  content of unsaturated  fatty acids.  They demonstrated  that 
unsaturated fatty acids have an inhibitory action on trypsin or leucoprotease which 
is proportional to their iodine values and which can be destroyed by saturating their 
double bonds.  But that lipoids are not concerned in the antiproteolytic power of 
serum was shown by Meyer (1909),  Cobliner (1910),  and Teale and Bach (1919-20). 
They demonstrated that lipoid solvents destroyed rather than extracted serum anti- 
protease; that lipoid solvents had no such effect on dried serum; and that the kinetics 
of the action of unsaturated fatty acids on trypsin is very different from that of serum. 
A fourth line of investigation was opened by Bayliss' discovery (1904), (confirmed 
by Abderhalden and Gigon (1907))  that trypsin is inhibited by the products of protein 
digestion.  Bayliss assumed that amino acids were responsible.  This led Rosenthal 
(1910) to suggest that serum owes its antiproteolytic action to its amino acid content 
("amino acid theory").  But Waiters  (1912)  and Northrop  (1921-22)  showed that 
the amino acids themselves have little,  if any, effect on tryptic action.  Northrop 
demonstrated  that some other constituent of the digest mixture,  (unidentified,  but 
apparently a  polypeptide), is responsible,  combining reversibly with  trypsin in ac- 
cordance with  the law of mass action.  Shortly afterwards  (1922-23)  Hussey and 
Northrop observed that the antitrypsin of normal serum behaves quantitatively like 
the trypsin inhibitor produced during the tryptic digestion of proteins.  More recently 
Northrop and Kunitz  (1932-33) have isolated a  polypeptide trypsin inhibitor from 
the pancreas, and Schmitz (1938),  employing their method, has extracted from beef 
blood small amounts of a substance resembling pancreatic trypsin inhibitor. 
2.  Physiological and Pathological Variation 
Widespread attention was first drawn to variations in the antiproteolytic activity 
of the serum  by the observation  of Brieger  and  Trebing (1908)  that  this activity 
increases markedly in the presence of malignant tumors.  This was repeatedly con- DAVID GROB  407 
finned, and was, for a time, unfortunately used as a diagnostic test for malignancy. 
However, it was not long before a similar increase was observed in many cases of acute 
infection, especially if accompanied by high fever (Hort, 1909); anemias  (Brenner, 
1909); late syphilis  (Fuerstenberg  and Trebing, 1909); tuberculosis and hyperthy- 
roidism (Waelli, 1917); organic diseases of the central nervous system (Bolten, 1918); 
anaphylaxis (Pfeiffer and Jarisch, 1913) ; protein shock therapy (Jobling and Petersen, 
1914); x-ray irradition (Herzger, 1924) ; pregnancy (Gr'~fenberg,  1909), especially when 
complicated by eclampsia; after very severe muscular exercise (Preti, 1912); and just 
before menstruation (Daniel and Florian,  1935-36).  An increase after meals and a 
decrease during starvation have been reported by Glaessner (1903) Rosenthal (1910) 
and Remedi and Bolognesi (1911).  The significance of these variations in the anti- 
proteolyfic activity of the blood has been little understood, although speculation has 
been rife.  It has been regarded by many as an indicator of cachexia, especially in 
chronic diseases. 
II.  DATA  ON  EXPERIMENTAL  VARIATION 
1.  Da~mination  oJ A~iproteolytic  Aaivity 
It has been shown (Robertson, 1912) that the refractive index of a solution 
of sodium easeinate is unaltered by tryptic digestion.  It is possible to esti- 
mate the extent of hydrolysis in such a  solution by precipitation of the undi- 
gested casein and determination of the refractive index of the filtrate.  The 
amount of casein digested is proportional to the difference between the index 
of refraction of this filtrate, and that of a  control filtrate, from which the 
casein is precipitated at once. 
The antitryptic action of a given serum may be measured by its suppression 
of casein digestion as compared with a similar solution in which the serum is 
replaced by saline (Robertson and Hanson, I918). 
The contribution of the serum protein to the substrate (a factor neglected 
by Robertson and Hanson) may be corrected for by a  third digest solution 
which contains an equal amount of serum whose antitryptic activity has been 
entirely destroyed by heat (serum diluted and heated at 80°C for 10 minutes). 
The contribution of the trypsin to the index of refraction (aside from its en- 
zymatic activity) may be corrected for by adding trypsin to the control whose 
casein is precipitated at once. 
The refractometric measurements indicate the extent of protease, but not of 
peptidase activity, and hence will allow investigation of the antiprotease action 
of serum only.  However, Jobling, Petersen, and Eggstein (1915)  have dem- 
onstrated the absence of antipeptidase activity by the serum.  In fact, the 
serum contains a small amount of active peptidase (Jobling and Strouse, 1912). 
The formula derived by Robertson and Hanson (1918) for the determination 
of the antitryptic activity of serum has been found by Fine (1931) and others 
to provide only an approximation of the true value, and to be quite unreliable 
when the concentration of serum is below 10 per cent. 408  ANTIPROTEOLYTIC  ACTIVITY  O~F  SERU'~.  I 
The following derivation of a formula for antiproteolytic activity, based on 
Hussey  and  Northrop's  convincing  demonstration  (1922-23)  that  tryptic 
protease and its inhibitor in serum combine reversibly in accordance with the 
law of mass action  (the inhibitor serving as a  "buffer" of the enzyme), may 
perhaps more accurately serve the desired purpose. 
If we assume that one molecule of tryptic protease (T) combines reversibly 
with one molecule of serum antiprotease (.4') to form one molecule of protease- 
antiprotease compound (TA'): 
or 
By the law of mass action 
T 4- A' ~  TA'. 
Cr X CA, 
CTA  r 
If: E  =  concentration of total trypsin (free and combined) 
T  =  concentration of free (and hence active) trypsin 
A  =  concentration of total antiprotease (CA, 4- CTz,) 
We may rewrite the equilibrium  equation as: 
(r)(a -  (•-  r)) 
=K 
E--T 
The value of E  is known.  T  is calculated from the experimental  results 
with the aid of Schutz's "law": 
X  ffi kV~  (at constant incubation time) 
where X  =  amount of protein digested. 
and T  =  concentration of free enzyme. 
Table I  illustrates the calculation.  The total volume of each solution was 
3 cc.  In each serum-added series the serum was at 1.33 per cent concentration. 
All mixtures were at pH 8 (phosphate buffer), and were incubated for 4 hours 
at 37°C.  The undigested casein of each was precipitated with acetic acid and 
filtered  off.  The  index  of  refraction  of  each  filtrate  was  then  determined. 
These readings were corrected as previously described. 
It is seen that complete digestion of 50 mg./cc, of sodium caseinate resulted 
in an increase in the index of refraction of the solvent of 0.0064 units, so that 
an increase of 0.0001 unit corresponds to the digestion of 0.78 mg./cc, of casein. 
This enables easy calculation of X, the concentration of digested casein, and DAVID  GROB  409 
X 
of ~, which is seen to be constant, (until excess enzyme was added).  Since 
X  control  X  serum 
~¢/~  -  ~v/~  , T is readily calculated for each concentration of enzyme. 
This leaves two unknowns in the equilibrium equation, A  and K.  A is constant 
for any one serum so that values for E  and T  can be entered for two different 
enzyme concentrations  (calculated for  T  >  0.0002  mg./cc.,  since concentra- 
tions of active enzyme smaller than  this were  considered negligible), and  K 
determined by eliminating A  by subtraction.  This was done for several sera, 
and  K  was  relatively constant  at  0.0018.  Using  this  value  for  K,  A  was 
calculated for these and other sera, and was constant for each serum  (within 
TABLE I 
The Effect of Serum on Varying Concentrations  of Trypsin 
1 
2 
3 
4 
5 
6 
7 
(E) 
Con- 
i  cen° 
tration 
i  of  crude 
tryp- 
mg./ 
i  cG. 
0 
0.017 
0.033 
o.0671 
O. 133i 
O. 167 
0.200 
Con- 
cen- 
tmtion 
of 
casein 
50 
50 
50 
50 
50 
50 
50 
Control  (no serum) 
I.R.*  (DX)  X 
gested ~1 
~seln 
mg./ 
cc. 
1.3338  0 
1. 3360 17.6 
1.3370 25.0 
1.3383  35.1 
1. 340~ i8.4 
1. 3402 50 
1.3402  50 
I.R. 
m  1.3338 
135 1.3339 
1391.3340 
135 1.3340 
134 1.3350 
122 1.3360 
Serum 1  Serum 2 
(1.33 per cent)  (1.33 per cent) 
X  T 
0 
0.78 
1.6 
1.6 
9.4 
14.8 
0.000036 
0.00014 
0.O0014 
0.005 
0.014 
A  I.R. 
--  1.3338 
--  [.3338 
--  [1.3340 
1.3340 
0.179  t.3358 
0.172  1.3368 
113 1.3370 25  0.034  0.176  1.3380 
X  T 
0 
0 
0.00014 
0.00014 
15.6  D.013  0.13; 
23.4  0.031 0.144 
32.7  !0.060 0.144 
* Index of refractiOn. 
the error of the index of refraction--about 5  per cent)  regardless of the  con- 
centration of enzyme. 
A  represents the concentration of serum antiprotease in the digest mixture. 
It  cannot  be  expressed in  grams or other definable unit.  The  law  of mass 
action is defined in molarity, but since it is not possible to accurately express 
concentration  of trypsin or casein in moles, milligrams per cubic centimeter 
were used throughout,  resulting in a  change in the constants,  but not in the 
validity of the equation.  The concentration of antiprotease in the serum can 
be represented as 
A 
C 
where S  -- concentration of antiprotease in serum (units/cc.) 
A  -- concentration of antipmtease in digest mixture (units/cc.) 
C  ffi cc. of serum in 1 cc. of digest mixture. 410  ANTIPROTEOLYTIC  ACTIVITY OF SERUM.  I 
TABLE II 
The Antitr'~ptic Activity  of Varying  Concentrations of Serum 
mg.~c. 
0.067 
0.067 
0.067 
0.067 
0.067 
0.067 
0.067 
Casein 
mg./~. 
50 
50 
5O 
5O 
50 
5O 
50 
Serum 3 
~  cen$ 
13.33 
6.67 
3.33 
1.67 
0.83 
0.42 
0.21 
I.R. 
1.3340 
1.3340 
1.3340 
1.3340 
1.3358 
1.3371 
1.3376 
0.00014 
0.00014 
0.00014 
0.00014 
0.014 
0.039 
0.052 
Control As in  Table I) 
O. 054 
0.028 
O. 015 
0.133  50  1.33  1.3375  0.049  0.085 
0.200  50  1.33  1.3394  0.113  0.087 
A  S 
6.8 
7.0 
7.5 
6.6 
6.7 
SERUM 
NQ:.2 
0  0.02  0.04  0.06 
T 
CH~mT 1.  The effect of serum on trypsin 
Table II illustrates the approximate constancy of S, regardless of the concen- 
tration of serum (provided that the change in the index of refraction is greater DAVID  GROB  411 
than the limit of accuracy of the measurement).  Measurements over a  wider 
range, however, show relatively more activity at low concentration  than at 
high, in accordance with the law of mass action. 
In Chart 1, the values for T and E given in Table I are plotted against each 
other.  Similar curves, of varying initial slopes, were obtained for the many 
~E (i.e., the slope  other sera studied.  It is evident that the extent to which 
of  the  curve)  exceeds  1  is  dependent  on  the  concentration of antiprotease 
present.  When T is small compared to E, i.e. when small amounts of trypsin 
are acting in the presence of serum, (E-T) approaches E, and A becomes pro- 
portional to E, producing a straight line curve whose slope (--ET) is proportlonal 
to  the concentration of antiprotease.  As E  increases,  T  increases,  and  the 
reaction 
T  -t- A' ~  TA' 
is driven toward the right.  The concentration of free antiprotease approaches 
zero, and the curve approaches a straight line with a slope of 1, increments of 
E  producing equal increments of T.  The shape of the curve reflects the fact 
that the greater the concentration of trypsin, the less is the per cent inhibition, 
despite the higher total concentration of trypsin inhibited. 
The calculation of S with the aid of the above formula is not limited to the 
refractometric method of following digestion, but should be equally applicable 
to any method that measures protease activity. 
2.  Procedure and Resulls 
Reports on the variation of antiproteolytic activity in response to injection 
of trypsin have been far from unanimous.  This may in large part be due to 
failure to  appreciate  that  normal  variations in  antiproteolytic activity are 
constantly occurring, that different samples of  equally active crude trypsin 
are frequently inhibited to different extents by the same serum (Young, 1918), 
and that the choice of method has a very important effect on the  results ob- 
tained (Fine,  1930). 
Hanson (1918) reported that the normal variation in antitryptic activity of 
the serum of several rabbits over a  period of weeks was approximately 50 per 
cent.  He also reported that subcutaneous injection of large amounts of crude 
trypsin resulted in a marked fall in the antitryptic activity, followed, if injec- 
tion was continued, by a  rise within a few days.  This rarely exceeded three 
times the average normal variation during a  similar period.  Then,  despite 
continued injection, a  rapid return to the normal range occurred.  These re- 
sults have been confirmed by some workers, and refuted by others. 
The effect on the antitryptic activity  of the following procedures was studied, 
and it was hoped that this might not only indicate the existence and magnitude 412  ANTIPROTEOLYTIC  ACTIVITY  OF SERUM.  I 
of a response to trypsin, but might also furnish a  clue to the mechanism of the 
action of trypsin and  to  the nature  of the antitryptic substance:  (1)  Intra- 
muscular  injection  of  trypsin.  (2)  Intravenous  injection  of  trypsin.  (3) 
TABLE III 
Daily Normal Variation in A ntiproteolytic A aivity 
Day .................. 
Rabbit 1  ........ 
II  2 ........ 
~  4  ........ 
1 
6.0 
3.5 
5.3 
6.8 
2 
7.1 
4.8 
5.1 
6.6 
3  4  5  6 
7.6  18.1  [6.3  5.7 
4.5[3.8  2.8  3.0 
4.5  4.9  3.5  4.7 
8.2  16.8 [5.6  5.0 
7 
5.2 
4.2 
4.8 
5.7 
Average daily variation 
Units  Per cent 
0.8  12 
0.8  21 
0.7  15 
0.95  15 
TABLE IV 
Response to Intramuscular Injection of Trypsin (25 Mg./ Day; 2.5 Cc. of I  Per Cent Solution in 
0.85 Per Cent NaCl; Seitz Filtered; Sterile) 
Rabbits 1-6.  Daily injection of active trypsin for 52 days. 
7 and 8.  Daily injection of active trypsin for 30 days. 
9 and 10.  Daily injection of denatured trypsin for 52 days. 
Before  injection 
Day  ................ 
Rabbit  1 ....... 
~l  3 ...... 
~  5 ...... 
"  7 ...... 
"  8 ...... 
"  10 ...... 
7  4  1 
~.07.65.2 
t.5 3.84.2 
5.34.94.8 
5.86.85.7 
5.2  -- 6.2 
5.8 -- 6.0 
7.2  --  8.1! 
5.5  -- 5.7! 
5.7  -- 5.3 
5.0  --  6.6 
Daily  injection 
6  11 
5  .---8 6 .Zi6 .--5 
i.ol3.515.2 
5.5 6.216.0 
5.0[5.316.3 
6.61--16.8 
6.71--17.0 
9.11il9.6 
6.01 -- 16.4 
5.01  --  14.2 
6.21- 17.5 
16  I  21  26 
7.;  8.6]  12.2 
7A  9.01 13.1 
6. ~.  9.31 11.6 
6.1  9.81 13.6 
--  7.61  -- 
--  7.31  -- 
--  0.31  -- 
--  8.21  -- 
--  6.01  -- 
--  7.2]  Died 
31 
3.0 
13.5 
13.3 
13.3 
11.0 
10.8 
i 
i 
14.0 
12.9 
4.9 
Mter  injection 
I 
L0.2  8.81 8.1  9.0 
9.8  8.51 8.~  8.8 
k0.8  9.0l  9.:  9.5 
L2.1  0.011A  0.8 
9.1  8.0  E  d 
8.81  7.9  8.,  8.5 
8.1  7.0  7.~ 
6.6  6.2  5.1 
--  6.7  --  5.8 
~6/4129/7 
~.115.2 
i.415.1 
r.2]i.7 
t.217.0 
5.617.0 
! 
--i-- 
Oral administration of trypsin.  (4)  Denatured  trypsin,  (a)  administered in- 
tramuscularly,  (b)  administered intravenously,  (c)  administered orally. 
In addition, the local reaction to trypsin injection was studied at different 
blood levels of antiproteolytic activity. 
The results obtained are recorded in Tables III-VII.  Antiproteolytic activ- 
ity is expressed in S  units/cc,  of serum.  Crude trypsin (Fairchild) was used 
throughout. TABLE V 
Response to Oral A dmCnistration of Trypsin (200 Mg./Day da Stomach Tube) 
Rabbit 1-4.  Daily administration of active trypsin for 4 days. 
5 and 6.  Daily administration of active trypsin for 8 days. 
7 and 8.  Daily administration of denatured trypsin for 4 days. 
Before  Daily administration  Mter 
Day .................  2  3  4 
Rabbit 1 ........ 
"  2 ........ 
cc  3 ........ 
~  4 ........ 
"  5 ........ 
"  6 ........ 
"  7 ........ 
"  8 ....... 
1 
7  8.3 
60  6.5 
75  8.3 
70  6.8 
77  7.9 
50  5.8 
66  7.5 
62  5.5 
10.3 
6.8 
9.8 
10.3 
10.4 
6.3 
7.3 
6.3 
10.5 
10.3 
10.8 
11.5 
10.1 
8.9 
8.5 
4.9 
12.0 
11.6 
14.8 
10.6 
14.8 
12.7 
6.8 
5.3 
2/6 
12.5 
12.6 
10.2 
8.1 
14.6 
13.1 
'7.6  -- 
7.1.  -- 
4/8 
10.9 
10.6 
9.3 
7.0 
14.4 
12.5 
6/2 
10.3 
7.5 
8.0 
7.2 
14.0 
12.0 
F 
m 
915 
7.9 
7.2 
6.4 
6.1 
8.3 
8.7 
m 
12/8 
8.5 
4.2 
TABLE VI 
Response to Intravenous Injection of Trypsin (50 Mg./  Day) 
Rabbits 1-3".  Daily injection of active trypsin for 15 days. 
4 and 5.  Daily injection of denatured trypsin for 15 days. 
Before  Daily administration  After 
Day ........................  2 
Rabbit 1 ............ 
~  2 ............ 
u  3 ............ 
"  4 ............ 
"  5 ............ 
1 
7.6 
7.0 
5.8 
4.5 
4.3 
1 
8.0 
6.1 
6.4 
5.1 
6.2 
3 
8.9 
5.5 
4.7 
5.8 
Died 
7 
8.6 
Died 
7.3 
4.9 
10 
8.0 
8.1 
5.6 
15 
9.1 
8.3 
4.0 
8.2 
7.7 
3.4 
TABLE VII 
Local Reaction 24 Hours  after the Subcutaneous Injection of  Trypsin  (25 Mg.)  (g.5  Cc.  of 
1 Per Cent Solution in 0.85 Per Cent NaCl, Seitz Filtered)  at Different Blood Levels of 
A ntiproteolytic A ctivity 
Rabbit 1  Rabbit 2 
Size of resulting  Day  S  Size of resulting 
Day  S  ulcer (ram3)  ulcer (ram..) 
1  4.3  250  1  9.6  70 
4  7.0  30  3  6.9  320 
5  9.3  18  13  11.2  6 
Rabbit 3  Rabbit 4 
Size of resulting  Day  S  Size of resulting  '  Day  S  ulcer (mm3) 
ul<er (ram.') 
1  3.8  I  1000  1  8.8  240 
13  9.3  ]  250  11  10.8  130 
19  8.0  ]  320  17  12.0  90 
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IIL  DISCUSSION 
The results  recorded in the tables  are reproduced in  part in Charts 2 to 4, 
and they show the following: 
1.  Daily variations in antiproteolytic activity of approximately 20 per cent 
may be considered to be normal, so that experimental variations must exceed 
this in order to be significant.  There is not sufficient data to evaluate the 
14 
12 
11 
t(: 
7 
6 
5 
4 
0 
A~--ff,  IJECTIONS STOPPED 
~,~  RABBIT NO.7 
///  \\\  INJEGTION~  STOPPED 
RABBIT NO.7  ~//  \ ~  FOR  RABBIT NO. I 
• 
TIME IN  DAYS 
CI~.R~ 2.  Response to intramuscular injection of trypsin 
average variation over days and weeks, but there is strong indication that this 
rarely exceeded 50 per cent of the average value. 
2.  Daily intramuscular injection of a  solution of 25  mg. of crude trypsin 
produced little significant change in the antiproteolytic activity for about the 
first 11 days.  Following this period the activity gradually increased, reached 
a maximum (representing an increase of from 70 per cent to 250 per cent over 
the average normal value) at about the 4th week, and then declined during 
the next 10 days to a value which was only about 40 per cent to 120 per cent 
above the average normal, and remained relatively fixed at this level during 
the next 2  weeks.  If the injections were stopped when the antiproteolytic DAVID GROB  415 
activity was at its height, the activity fell off much more sharply than if injec- 
tion were maintained, and returned to the normal range within a week.  Cessa- 
tion of injections at the 52nd day also resulted in return to the norm in less 
than a week.  The intramuscular injection of denatured trypsin did not have 
any significant effect on the antiproteolytic activity of the serum. 
5 
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CHART 3.  Response to oral administration of trypsin 
3.  Daily oral administration of 200 rag. of trypsin resulted in a  rapid  rise 
in antiproteolytlc activity within the first day or two, which was maintained 
during the 4  or 8 days of administration, and which returned to the normal 
range  within  a  week  after  this  was  stopped.  Denatured  trypsin  had  no 
such effect. 
4.  Daily intravenous injection of 50 mg. of trypsin produced no variation in 
activity  comparable  to  intramuscular  or  oral  administration,  Denatured 
trypsin was likewise without effect. 
5.  The subcutaneous injection of 25 rag. of crude trypsin into animals at 
different blood levels of antiproteolytic activity resulted  in the production of 416  ANTIPROTEOLYTIC  ACTIVITY OF  SERUM.  I 
ulcers varying from 6 mm3 in area to large sloughs up to  1000 ram3 in area. 
Microscopic examination  of the underlying  subcutaneous  tissues  showed  in- 
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CHART 4.  Local reaction to trypsin 
flammation and  necrosis,  corresponding  in  severity to  the  size of the  ulcer. 
Comparison between the size of the ulcer and the antiproteolytic activity of 
the serum shows a  rough inverse correlation (in the four animals studied)  be- 
tween the activity of the serum of any one rabbit and the size and severity of 
the ulcer in that animal, low antiproteolytic activity being associated with a 
severe local reaction, and ~/ce versa. DAVID  GROB  417 
The experimental results outlined above strongly indicate that an antipro- 
teolytic response to trypsin occurs only when the enzyme is active, and when it 
is administered to the animal in such a way as to allow enzymatic action to 
occur.  The ineffectiveness of intravenous injection of trypsin could well be 
explained by the prompt neutralization of the enzyme by the antiproteolytic 
action of the circulating blood and its maintenance in inactive combination due 
to the excess of antiprotease.  The decline in antiproteolytic activity after a 
maximum has been reached  as a result of daily intramuscular injection could 
also  be  explained  by decreased proteolysis  by  the  enzyme,  here  resulting 
from the increased neutralizing action of the blood,  and hence of the exudate 
that responds to the local necrotizing action of trypsin. 
The work of Baylis.s (1904) demonstrating that trypsin is inhibited by the 
products of protein digestion, and of Northrop (1921-22) identifying the tryp- 
sin inhibitor as a polypeptide, has already been referred to.  The results of 
experimental variation of antiproteolytic activity that have been described are 
compatible with this mechanism of antiprotease production.  They suggest 
that the products of protein hydrolysis in the intestine and parenterally are 
an important factor in the antiproteolytic activity of the serum.  These pro- 
ducts are most likely polypeptides similar to the trypsin inhibitor produced in 
vitro by Northrop.  The rapid increase  in serum antiprotease following  oral 
administration of  trypsin does  not  contraindicate a  polypeptide inhibitor, 
since the intestinal absorption of peptides, and even of small amounts of larger 
molecules, is now recognized  (Sussman  et al.,  1928). 
If the above mechanism of antiprotease production is true, it would be ex- 
pected that oral administration of trypsin to animals deprived of food would 
produce no rise in antiproteolytic activity.  Two rabbits that were so studied 
after 4 days of starvation showed no increase in serum activity after 3 days of 
trypsin per os  (200 mg./day).  Unfortunately, they died on the 8th day of 
starvation, so that the experimental results are only suggestive. 
The physiological and pathological variations in the antiproteolytic activity 
of the serum that have been reported are not at variance with a "proteolytic" 
theory of the origin of this activity.  The postprandial increase in activity and 
the decrease that occurs during starvation (Glaessner,  1903; Rosenthal, 1910; 
and Remedi and Bolognesi, 1911) would be attributed to the r61e that intestinal 
digestion  of proteins plays in the production of the antiprotease.  The pro- 
teolytic enzymes that are abundant in placental tissue (Maeda, 1923) would 
be responsible for the increase during pregnancy.  The increase in hyperthy- 
roidism  (Waelli,  1912), in  many  cases  of  acute  infection  with high  fever 
(Hort, 1909), and after very severe muscular exercise (Preti, 1912) would be due 
to increased  protein catabolism,  which might also result in the formation of 
antiprotease.  That the marked rise accompanying malignancy may well be 
due to resultant tissue necrosis and autolysis is supported by the observation 418  ANTIPROTEOLYTIC  ACTIVITY  OF  SERUM.  I 
of Raab (1935) that the increase of serum antiproteolytic activity in malignant 
disease is rougly proportional to the degree of disintegration and proteolysis 
in the tumor.  The importance of tissue autolysis in pathological increases of 
antiproteolytic activity has been emphasized by Meyer (1909), by Braunstein 
and Kepinow (1910), who increased serum activity by injecting intravenously 
the  products  of  autolysis  of  tumors,  liver  tissue,  and  other  protein-rich 
substrates, and by Opie, Barker, and Dochez (1911),  who showed that sub- 
stances such as chloroform, which cause necrosis of liver cells, cause a parallel 
increase in serum antiproteolytic activity.  Finally the increased serum anti- 
protease observed in advanced tuberculosis (Waelli, 1912), and in other condi- 
tions associated with "cachexia," may perhaps be due to the increased protein 
catabolism associated with the wasting that is a  prominent feature of these 
conditions. 
That the increase in antiproteolytic activity in many of the above conditions 
might, at least in part, be due to decreased serum protease,  rather than  in- 
creased antiprotease, is contraindicated by the work of Falls (1915)  and  of 
Jobling, Petersen, and Eggstein (1915), who have reported that serum protease 
increases in many of these conditions. 
The possibility that antiprotease  is an antibody produced in  response  to 
trypsin is rendered highly unlikely by the nature, magnitude, and variation of 
the antiprotease response.  Nevertheless, precipitin tests between the serum 
of rabbits, before and after trypsin injections, and various dilutions of trypsin 
were performed.  Outside of a weak precipitin reaction with serum of animals 
that had received trypsin intravenously they were all negative, and the posi- 
tive precipitin reactions showed no parallelism  to  antiprotease activity.  It 
is furthermore probable that the antibodies that were observed were produced 
not in response to trypsin, but to other proteins in the crude trypsin, particu- 
larly since TenBroeck (1934) was unable to obtain positive precipitin reactions 
following injection of crystalline trypsin, although he obtained positive Dale 
anaphylactic tests.  And  that  such  antibodies are  responsible for the anti- 
tryptic activity of the serum and for the ability of injected rabbits to neutralize 
the local action of trypsin, as was believed by Achalme (1901)  and by Young 
(1918), seems very unlikely in view of the great dissimilarity between the anti- 
protease response to trypsin, described above, and the antibody response to 
the enzyme, described by TenBroeck. 
Northrop (1929-30)  has discovered that when pepsin is injected into an ani- 
mal it is almost immediately denatured, so that the antibodies which result 
are  largely antibodies  to  the denatured pepsin.  That  this  is probably not 
true in the case of trypsin is indicated by the failure of the precipitin reaction 
to  become  any more  positive  when  denatured  instead  of active  trypsin  is 
employed. 
Animals to whom trypsin had been previously administered did not show DAVID  GROB  419 
increased response when they received the enzyme again at a later date (by 
any route). 
A few findings present objections to the "polypeptide" theory of serum anti- 
protease.  Benetato,  a  M.  (1937)  have reported an inverse relationship  be- 
tween serum antiproteolytic activity and serum non-protein nitrogen.  How- 
ever, this work is at least partly refuted by the observations of Shono (1933), 
and, in any  event, awaits confirmation.  More serious objection is raised by 
the fact that serum antiprotease is not dialyzable, and is destroyed by heating 
serum (after dilution to prevent coagulation)  at 80°C.  for 10 minutes (Fuji- 
moto, 1918), neither of which would be expected if it were a simple polypeptide. 
This would be explained,  however, if the evidence advanced by Loiseleur and 
Colliard (1937)  that polypeptides in the blood are normally adsorbed to the 
plasma proteins is confirmed,  and  is shown to apply to serum antiprotease. 
Attempts which were made to dissociate such a combination by lowering  the 
pH of the serum (or of the plasma, which has the same antiproteolytic activity) 
below 3, at which pH the compound of trypsin and pancreatic trypsin inhibitor 
dissociates, resulted in an irreversible loss of antiproteolytic activity.  (This 
may perhaps  explain  the  small yield of crystalline  antitrypsln  obtained by 
Schm.itz's method of extraction.)  Some clue to the situation may be offered 
by the finding that when crystalline pancreatic trypsin-inhibitor (prepared after 
the method of Northrop and Kunitz, 1932-33) or crystalline serum antitrypsin 
(prepared  after  the method of Schmitz,  1938) was heated  at  80°C.  for  10 
minutes, it retained its activity, but the addition of a small amount of serum 
(and, to a lesser extent, of serum albumin) resulted in a marked loss of activity 
on heating.  Experiments investigating the effect of serum and of serum al- 
bumin on the dialyzability of the above crystalline compounds were unfortu- 
nately inconclusive.  However, M~lka  (1932) has reported that he was able 
to free trypsin from the trypsin-serum antiprotease  combination by dialysis 
of the antiprotease. 
Since serum antiprotease is not dialyzable, it should not be freely diffusible 
in the body except when inflammation,  or other pathological process, increases 
capillary  permeability.  Such  has  been found  to  be the  case.  Thus  Fazio 
and Chiarolaza (1910) have reported the absence of antiprotease from normal 
serous fluids and from most transudates, while Weinberg and Laroche (1909) 
have demonstrated its presence in exudates.  Muller (1907)  was the first to 
show the absence of antlprotease from normal cerebrospinal fluid, and Dochez 
(1909) the first to show its presence during meningitis.  The iatter's findings 
have been more recently confirmed by Kaplan eta/.  (1939),  who also found 
antiprotease in the cerebrospinal fluid of patients with brain tumors invading 
the meninges or ventricles.  (According to Waiter  (1929)  only such tumors 
as these increase the permeability of meningeal capillaries.)  The presence of 
a small amount of diffusible antiproteolytic substance in normal urine has been 420  ANTIPROTEOLYTIC  ACTIVITY OF SERITM.  I 
reported by Fujimoto (1918),  while numerous workers (e.g.,  Schippers,  1911) 
have reported the appearance of large amounts of antiprotease in pathological 
urine,  especially in nephritis. 
IV. SUMMARY 
1.  An equation is derived for the calculation of a  constant which, experi- 
mental results indicate, may be a  more reliable index of the antiproteolytic 
activity of serum than those equations hitherto used. 
2.  (a) Intramuscular administration of trypsin resulted in a slow rise in the 
antiproteolytic activity of the serum, followed by a  lesser decline.  (b)  In- 
travenous  administration  resulted  in  no  appreciable  variation.  (c)  Oral 
administration  resulted  in  a  rapid  rise,  which  was  sustained  during  the 
period of administration.  (d)  Intramuscular, intravenous, or oral administra- 
tion of denatured trypsin resulted in no appreciable variation.  (e)  The ex- 
tent of the local necrosis following subcutaneous injection of trypsin varied 
inversely with the antiproteolytic activity of the serum. 
3.  The experimental results indicate that the products of protein hydrolysis 
in the intestine and parenterally are an important factor in the antiproteolytic 
activity of the serum.  They also indicate that antibodies to trypsin are not 
an important factor in the antiproteolytic activity of the serum. 
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